Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer



Status:Recruiting
Conditions:Skin Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/30/2013
Start Date:October 2006

Use our guide to learn which trials are right for you!

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer


This phase II trial is studying how well giving cetuximab together with bevacizumab works in
treating patients with recurrent or metastatic head and neck cancer. Monoclonal antibodies,
such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Cetuximab and bevacizumab may also stop the growth
of head and neck cancer by blocking blood flow to the tumor. Giving cetuximab together with
bevacizumab may kill more tumor cells


PRIMARY OBJECTIVES:

I. Determine the objective response rate in patients with recurrent or metastatic squamous
cell carcinoma of the head and neck treated with cetuximab and bevacizumab.

SECONDARY OBJECTIVES:

I. Determine the progression-free and overall survival of patients treated with this
regimen.

II. Determine the levels of soluble epidermal growth factor receptor (EGFR) in blood samples
before and after dual EGFR and vascular endothelial growth factor inhibition.

III. Evaluate treatment-related toxicities of this regimen in these patients. IV. Collect
and bank blood samples for future correlative studies.

OUTLINE: This is a multicenter study. Patients receive cetuximab intravenously (IV) over 1-2
hours on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats
every 21 days in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples are collected at baseline to determine whether biomarkers on tumor
tissue and/or blood can be linked with clinical response and to measure signaling pathways
by reverse phase protein microarray. Epidermal growth factor receptor (EGFR) gene copy
number is assessed by fluorescent in situ hybridization (FISH) on tumor tissue pretreatment.
Blood samples are also collected at baseline and on day 21 of course 1 for analysis by
acridinium-linked immunosorbent assay (ALISA) to quantify serum p110 sEGFR protein levels.

After completion of study treatment, patients are followed every 2-3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Histologically or cytologically confirmed squamous cell carcinoma of the head and
neck

- Metastatic and/or recurrent disease

- Measurable disease defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques or ≥ 10 mm by CT scan

- Not eligible for curative-intent surgery or radiotherapy

- No tumors invading major vessels (e.g., carotid artery) by imaging studies

- No history of major, uncontrolled tumor-related bleeding despite locoregional
treatment

- Not at high-risk for recurrent tumor-related bleeding

- No known brain metastases

- ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

- Absolute neutrophil count ≥ 1,000/mm³

- Platelet count ≥ 75,000/mm³

- Bilirubin normal

- AST and ALT ≤ 5 times upper limit of normal (ULN)

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Urine protein: creatinine ratio ≤ 0.5 OR urine protein < 1,000 mg by 24-hour urine
collection

- INR < 1.5

- No history of gross hemoptysis (defined as bright red blood of ≥ ½ teaspoon) or
coagulopathy

- No history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis)

- No history of severe infusion reaction to a monoclonal antibody

- No CNS cerebrovascular ischemia or stroke within the past 6 months

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 4 weeks

- No significant traumatic injury within the past 4 weeks

- No unstable angina or myocardial infarction within the past 6 months

- No other malignancy within the past 3 years except curatively treated squamous cell
or basal cell skin cancer or in situ cervical cancer

- No uncontrolled illness including, but not limited to, any of the following:

- Serious nonhealing wound, ulcer, or bone fracture

- Symptomatic congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Clinically significant peripheral vascular disease

- Active serious infection

- Other coexisting medical or psychiatric condition that would preclude study
compliance

- No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg) despite a stable
regimen of antihypertensive therapy

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after
completion of study treatment

- At least 3 weeks since prior biologic/targeted agents

- At least 3 weeks since prior radiotherapy

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- At least 4 weeks since prior major surgical procedure or open biopsy

- At least 3 months since prior monoclonal antibody therapy

- No prior cetuximab, bevacizumab, or other epidermal growth factor receptor or
vascular endothelial growth factor-targeting agents

- No more than 1 prior adjuvant or neoadjuvant chemotherapy or chemoradiotherapy
regimen (may have included biologic therapy or a targeted agent)

- No more than 1 prior treatment regimen (e.g, chemotherapy or biologic/targeted
therapy) for recurrent or metastatic disease

- No concurrent major surgery

- No concurrent therapeutic anticoagulation except prophylactic warfarin 1 mg/day

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer agents or therapies
We found this trial at
4
sites
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials